Preferred Label : Anti-EGFR/c-Met/TOP1i ADC AZD9592;
NCIt synonyms : Bispecific ADC AZD9592; Anti-EGFR/c-Met ADC AZD9592;
NCIt definition : An antibody-drug conjugate (ADC) composed of a bispecific antibody targeting both
epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR;
c-Met) and conjugated to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic
activity. Upon administration, anti-EGFR/c-Met/TOP1i ADC AZD9592 simultaneously targets
and binds to the extracellular domains of wild-type (WT) or certain mutant forms of
both EGFR and c-Met expressed on cancer cells. Upon binding and internalization, the
TOP1i moiety is released, binds to TOP1 and stabilizes cleaved DNA-TOP1 complexes.
This prevents DNA re-ligation, induces irreversible DNA strand breaks, prevents DNA
repair, and leads to cycle arrest and apoptosis specifically in tumor cells expressing
EGFR and c-Met. EGFR and c-Met, both upregulated or mutated in a variety of tumor
cell types, play key roles in tumor cell proliferation.;
Molecule name : AZD-9592; AZD 9592;
NCI Metathesaurus CUI : CL1905620;
Origin ID : C192091;
UMLS CUI : C5784891;
Semantic type(s)
- concept_is_in_subset
- has_target
